Individuals with dementia live and frequently die in community settings. 1 key finding →
Design: prospective cohort Participants: 524 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Social Security and Medicare actuaries should account for the growing number of beneficiaries with multiple chronic conditions when determining population projections and trust fund solvency. 2 key findings →
Design: cohort study Participants: 1,372,272 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We identified several subgroups of the population who are particularly susceptible to temperature extremes, including persons with atrial fibrillation. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
High homocysteine levels were not associated with AD and were not related to a decrease in memory scores over time. 4 key findings →
Design: longitudinal study Participants: 679 Evidence: moderate
Full summary, score breakdown and related studies → Original source
64/100
Successful discharge of beneficiaries with ADRD increased from 43.4% in 2007 to 53.9% in 2015 (average annual percent change (AAPC) = 2.1 (95% CI = 2.0-2.2)); those without ADRD also increased (from 59.1% to 63.6%, AAPC = 0.9 (95% CI = 0.7-1.1)) but not as fast as those with ADRD (P < .01). 4 key findings →
Design: cross-sectional Participants: 17,043 Evidence: low
Full summary, score breakdown and related studies → Original source
Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD. 1 key finding →
Design: cohort Participants: 95,853 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
63/100
Community dwellers with dementia were more likely than those without dementia to receive life-sustaining treatments in their last 90 days of life (advanced dementia: OR = 1.83 [1.42-2.35]; non-advanced dementia: OR = 1.16 [1.01-1.32]). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We aimed to conduct a cost-utility analysis of DREAMS START compared with treatment as usual (TAU). 4 key findings →
Design: RCT Participants: 377 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Even in persons who are currently nondisabled, a simple measure of lower extremity performance is predictive of subsequent hospitalization, especially for geriatric conditions. 2 key findings →
Design: cohort study Participants: 3,381 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study provides a comprehensive estimate of the excess costs that result from providing informal dementia care in the community. 3 key findings →
Design: longitudinal study Participants: 2,043 Evidence: moderate
Full summary, score breakdown and related studies → Original source
61/100
This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US. 4 key findings →
Design: modelling Participants: 31,028 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neither targeted lecanemab treatment nor treatment unrestricted by APOE ε4 genotype is cost-effective vs SoC alone for patients with MCI or mild dementia due to AD. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
APPLE-Tree has a high probability of being cost-effective for a 1-point NTB gain, a difference previously associated with a three-fold reduction in 5-year dementia risk. 3 key findings →
Design: RCT Participants: 746 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results provide evidence for the efficacy and cost-effectiveness of extended nursing roles in dementia care, demonstrating that extended nursing roles reduce unmet needs and improve quality of life. 3 key findings →
Design: RCT Participants: 417 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
60/100
Patients with BP are more likely to have various neurological diseases, schizophrenia and psoriasis prior to the diagnosis of BP, supporting associations found in other studies. 3 key findings →
Design: case-control study Participants: 3,485 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Newly diagnosed DM was associated with increased risk of AD. 5 key findings →
Participants: 71,433 Evidence: moderate
Full summary, score breakdown and related studies → Original source
PET participants lived longer in community (0.26 years, 95% confidence interval [CI]: 0.05 to 0.45) and overall (0.15, CI: 0.02 to 0.27), but did not have statistically different health insurance (€703, CI: -3974 to 5045) or total costs including institutionalization (-€8258, CI: -20,622 to 3377). 5 key findings →
Participants: 440 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Delirium is a complex clinical syndrome characterised by disturbed consciousness, cognitive function, or perception. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The huge costs of dementia worldwide place enormous strains on care systems and families alike.
Full summary, score breakdown and related studies → Original source Free full text
In addition to an overview of the results, we briefly outline the methods applied to the concept of resting-state functional connectivity. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This review corroborates previous understanding that AD burden is high for both society and healthcare providers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Ascertainment of etiologic dementia subtype may inform hereditary risk and facilitate financial and care planning. 2 key findings →
Participants: 226,604 Evidence: low
Full summary, score breakdown and related studies → Original source
The lack of consensus on measuring QoL in dementia suggests a need for a broader, more rigorously tested QoL measure. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
The literature indicates that people with YOD and their caregivers face a wide range of difficulties during the disease process. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sample sizes for individuals with comorbid insomnia ranged from 23,168 (T2DM) to 3,015 (ADRDs). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events